Beijing Biostar Pharmaceuticals Co., Ltd.（“BIOSTAR PHARM”, Stock code:02563.HK）completed its IPO and H-share listing on the Main Board of Hong Kong Stock Exchange on October 31, 2024.

As the PRC legal counsel and Hong Kong legal counsel to the underwriter, Jingtian & Gongcheng has provided comprehensive and high-quality legal services for the company's listing through coordination between domestic and international teams.